PMID- 30559266
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Dec 17
TI  - Everyone with type 1 diabetes should have access to a flash glucose device.
PG  - k5204
LID - 10.1136/bmj.k5204 [doi]
FAU - Charlton, Mary
AU  - Charlton M
AD  - Diabetes Centre, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK.
LA  - eng
PT  - Letter
DEP - 20181217
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
COIS- Competing interests: MC has family members who use various glucose monitoring
      devices.
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 10.1136/bmj.k5204 [doi]
PST - epublish
SO  - BMJ. 2018 Dec 17;363:k5204. doi: 10.1136/bmj.k5204.

PMID- 30552780
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Dec 15
TI  - Variability in sleep disturbance, physical activity and quality of life according
      to level of depressive symptoms in women with Type 2 diabetes.
LID - 10.1111/dme.13878 [doi]
AB  - AIMS: To examine (1) the prevalence of depressive symptoms in women with Type 2
      diabetes, (2) the associations between depressive symptoms and the following
      dependent variables: sleep disturbance; physical activity; physical
      health-related; and global quality of life, and (3) the potential moderating
      effects of antidepressants and optimism on the relationship between depressive
      symptoms and dependent variables. METHODS: Participants in the Women's Health
      Initiative who had Type 2 diabetes and data on depressive symptoms (N=8895) were 
      included in the analyses. In multivariable linear regression models controlling
      for sociodemographic, medical and psychosocial covariates, we examined the main
      effect of depressive symptoms, as well as the interactions between depressive
      symptoms and antidepressant use, and between depressive symptoms and optimism, on
      sleep disturbance, physical activity, physical health-related quality of life and
      global quality of life. RESULTS: In all, 16% of women with Type 2 diabetes
      reported elevated depressive symptoms. In multivariable analyses, women with
      depressive symptoms had greater sleep disturbance (P<0.0001) and lower global
      quality of life (P<.0001). We found evidence of significant statistical
      interaction in the models for quality-of-life outcomes: the increased risk of
      poor physical health-related quality of life associated with antidepressant use
      was stronger in women without vs with depressive symptoms, and the association
      between greater optimism and higher global quality of life was stronger in women 
      with vs without depressive symptoms. CONCLUSIONS: To improve health behaviours
      and quality of life in women with Type 2 diabetes, sociodemographic and medical
      characteristics may identify at-risk populations, while psychosocial factors
      including depression and optimism may be important targets for
      non-pharmacological intervention. This article is protected by copyright. All
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Danhauer, S C
AU  - Danhauer SC
AD  - Department of Social Sciences and Health Policy, Wake Forest School of Medicine.
FAU - Brenes, G A
AU  - Brenes GA
AD  - Department of Internal Medicine, Section on Gerontology and Geriatric Medicine,
      Wake Forest School of Medicine.
FAU - Levine, B J
AU  - Levine BJ
AD  - Department of Social Sciences and Health Policy, Wake Forest School of Medicine.
FAU - Young, L
AU  - Young L
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Section on
      Gerontology and Geriatric Medicine, UNC School of Medicine, Chapel Hill, NC.
FAU - Tindle, H A
AU  - Tindle HA
AD  - Division of General Internal Medicine and Public Health, Department of Medicine, 
      Vanderbilt University Medical Center, Nashville, TN.
FAU - Addington, E L
AU  - Addington EL
AD  - Department of Medical Social Sciences, Northwestern University Feinberg School of
      Medicine, Chicago, IL.
FAU - Wallace, R B
AU  - Wallace RB
AD  - Department of Epidemiology, University of Iowa College of Public Health, Iowa
      City, IA.
FAU - Naughton, M J
AU  - Naughton MJ
AD  - Division of Cancer Prevention and Control, Department of Internal Medicine, The
      Ohio State University, Columbus, OH.
FAU - Garcia, L
AU  - Garcia L
AD  - Department of Public Health Sciences, University of California Davis School of
      Medicine, Davis, CA.
FAU - Safford, M
AU  - Safford M
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY.
FAU - Kim, M M
AU  - Kim MM
AD  - Center for Biobehavioral Health Disparities Research, Department of Community and
      Family Medicine, Duke University, Durham, NC.
FAU - LeBlanc, E S
AU  - LeBlanc ES
AD  - Kaiser Permanente Center for Health Research NW, Portland, OR, USA.
FAU - Snively, B M
AU  - Snively BM
AD  - Department of Biostatistical Sciences, Division of Public Health Sciences, Wake
      Forest School of Medicine, Winston Salem, NC.
FAU - Snetselaar, L G
AU  - Snetselaar LG
AD  - Department of Epidemiology, University of Iowa College of Public Health, Iowa
      City, IA.
FAU - Shumaker, S
AU  - Shumaker S
AD  - Department of Social Sciences and Health Policy, Wake Forest School of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20181215
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/12/16 06:00 [entrez]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
AID - 10.1111/dme.13878 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Dec 15. doi: 10.1111/dme.13878.

PMID- 30552772
OWN - NLM
STAT- Publisher
LR  - 20190118
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Dec 15
TI  - Depressive symptoms and cerebral microvascular disease in adults with Type 1
      diabetes mellitus.
LID - 10.1111/dme.13879 [doi]
AB  - AIM: To assess the prevalence of, and risk factors for, depressive symptoms,
      comparing a sample of middle-aged adults with and without juvenile-onset Type 1
      diabetes mellitus, and to determine if depressive symptoms were associated with
      white matter hyperintensity volume among those with Type 1 diabetes. METHODS:
      Depressive symptoms and white matter hyperintensities were compared between
      adults (age range 30-65 years) with juvenile-onset Type 1 diabetes (n=130) and
      adults without Type 1 diabetes (n=133). The association of Type 1 diabetes with
      depression was computed before and after adjustment for white matter
      hyperintensities. Among the Type 1 diabetes group, the primary associations of
      interest were between depressive symptoms (Beck Depression Inventory score >/=10)
      and white matter hyperintensities (n=71), hyperglycaemia and physical activity.
      Associations between depressive symptoms and diabetes-related complications,
      cognitive impairment, smoking and self-reported disability were examined.
      Analyses were controlled for education, sex, age and antidepressant use. RESULTS:
      Depressive symptoms were more prevalent among those with vs those without Type 1 
      diabetes (28% vs 3%; P<0.001). White matter hyperintensities explained 40% of the
      association of Type 1 diabetes with depressive symptoms, while Type 1 diabetes
      had a direct effect of 68% on depressive symptoms. Among those with Type 1
      diabetes, depressive symptoms were related to white matter hyperintensity volume,
      a 16-year average HbA1c >/=58 mmol/mol (7.5%), and lower physical activity
      levels. Associations with other characteristics were not significant. CONCLUSION:
      These findings suggest a cerebrovascular origin for depressive symptoms in adults
      with Type 1 diabetes, perhaps triggered by hyperglycaemia. Future longitudinal
      studies should investigate whether targeting hyperglycaemia and physical
      inactivity alleviates depressive symptoms, possibly by slowing the development of
      cerebral microvascular disease, in people with Type 1 diabetes.
CI  - (c) 2018 Diabetes UK.
FAU - Nunley, K A
AU  - Nunley KA
AUID- ORCID: https://orcid.org/0000-0001-5848-7673
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Karp, J F
AU  - Karp JF
AD  - Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Orchard, T J
AU  - Orchard TJ
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Costacou, T
AU  - Costacou T
AUID- ORCID: https://orcid.org/0000-0001-9303-3810
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Aizenstein, H J
AU  - Aizenstein HJ
AD  - Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Jennings, J R
AU  - Jennings JR
AD  - Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
AD  - Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Rosano, C
AU  - Rosano C
AUID- ORCID: https://orcid.org/0000-0002-0909-1506
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
LA  - eng
GR  - R01 DK089028/National Institutes of Health
GR  - R37 DK034818/National Institutes of Health
GR  - RO1 HL101959-05/National Institutes of Health
PT  - Journal Article
DEP - 20181215
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/12/13 00:00 [accepted]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
PHST- 2018/12/16 06:00 [entrez]
AID - 10.1111/dme.13879 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Dec 15. doi: 10.1111/dme.13879.

PMID- 30552767
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Dec 15
TI  - The apparent low incidence of paediatric Type 2 diabetes in the Republic of
      Ireland is multifactorial.
LID - 10.1111/dme.13877 [doi]
AB  - We read with interest the study by Candler et al. [1], evaluating the incidence
      of paediatric Type 2 diabetes mellitus in the UK and Republic of Ireland. They
      identified an overall incidence in UK children of 0.72 per 100 000. Just two
      cases of paediatric Type 2 diabetes were reported in the Republic of Ireland
      during the study period compared with 104 cases in the UK, while the UK
      paediatric population is just 13-fold larger. Candler et al. speculate that the
      difference may be a consequence of the lower proportion of the Irish paediatric
      population who are of Asian (2.3 vs 9.8%) or black/Afro-Caribbean (2.9 vs 4.8%)
      ethnicity. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Walsh, N A
AU  - Walsh NA
AD  - Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath.
FAU - O'Dea, M I
AU  - O'Dea MI
AD  - Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath.
FAU - O'Grady, M J
AU  - O'Grady MJ
AD  - Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath.
AD  - Women's and Children's Health, School of Medicine, University College Dublin,
      Ireland.
LA  - eng
PT  - Journal Article
DEP - 20181215
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/12/16 06:00 [entrez]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
AID - 10.1111/dme.13877 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Dec 15. doi: 10.1111/dme.13877.

PMID- 30552111
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Dec 14
TI  - Circulating Exosomal miR-20b-5p is Elevated in Type 2 Diabetes and Could Impair
      Insulin Action in Human Skeletal Muscle.
LID - db180470 [pii]
LID - 10.2337/db18-0470 [doi]
AB  - MicroRNAs (miRNAs) are noncoding RNAs representing an important class of gene
      expression modulators. Extracellular circulating miRNAs are both candidate
      biomarkers for disease pathogenesis and mediators of cell-to-cell communication. 
      We examined the miRNA expression profile of total serum and serum derived
      exosome-enriched extracellular vesicles in people with normal glucose tolerance
      or type 2 diabetes. In contrast to total serum miRNA, which did not reveal any
      differences in miRNA expression, we identified differentially abundant miRNAs in 
      type 2 diabetes patients using miRNA expression profiles of exosome RNA (exoRNA).
      To validate the role of these differentially abundant miRNAs on glucose
      metabolism, we transfected miR-20b-5p, a highly abundant exoRNA in type 2
      diabetic patients, into primary human skeletal muscle cells. miR-20b-5p
      overexpression increased basal glycogen synthesis in human skeletal muscle cells.
      We identified AKTIP and STAT3 as miR-20b-5p targets. miR-20b-5p overexpression
      reduced AKTIP abundance and insulin-stimulated glycogen accumulation. In
      conclusion, exosome derived extracellular miR-20b-5p is a circulating biomarker
      associated with type 2 diabetes, which plays an intracellular role in modulating 
      insulin-stimulated glucose metabolism via AKT signaling.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Katayama, Mutsumi
AU  - Katayama M
AD  - Department of Physiology and Pharmacology Karolinska Institutet, SE-171 77
      Stockholm, Sweden.
FAU - Wiklander, Oscar P B
AU  - Wiklander OPB
AD  - Department of Laboratory Medicine, Karolinska Institutet, SE-141 83 Huddinge,
      Sweden.
FAU - Fritz, Tomas
AU  - Fritz T
AD  - Department of Clinical Physiology, Karolinska University Hospital, SE-171 76
      Stockholm, Sweden.
FAU - Caidahl, Kenneth
AU  - Caidahl K
AD  - Department of Clinical Physiology, Karolinska University Hospital, SE-171 76
      Stockholm, Sweden.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76
      Stockholm, Sweden.
AD  - Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Andaloussi, Samir El-
AU  - Andaloussi SE
AD  - Department of Laboratory Medicine, Karolinska Institutet, SE-141 83 Huddinge,
      Sweden.
AD  - Department of Physiology, Anatomy and Genetics, University of Oxford, OX13D
      Oxford, UK.
FAU - Zierath, Juleen R
AU  - Zierath JR
AD  - Department of Physiology and Pharmacology Karolinska Institutet, SE-171 77
      Stockholm, Sweden.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76
      Stockholm, Sweden.
FAU - Krook, Anna
AU  - Krook A
AD  - Department of Physiology and Pharmacology Karolinska Institutet, SE-171 77
      Stockholm, Sweden, Anna.Krook@ki.se.
LA  - eng
PT  - Journal Article
DEP - 20181214
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/11/29 00:00 [accepted]
PHST- 2018/12/16 06:00 [entrez]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
AID - db18-0470 [pii]
AID - 10.2337/db18-0470 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Dec 14. pii: db18-0470. doi: 10.2337/db18-0470.

PMID- 30552110
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Dec 14
TI  - Low Level Insulin Content Within Abundant Non-Beta Islet Endocrine Cells in
      Long-Standing Type 1 Diabetes.
LID - db180305 [pii]
LID - 10.2337/db18-0305 [doi]
AB  - Although most type 1 diabetes (T1D) patients continue to produce small amounts of
      insulin decades after disease onset, very few beta-cells persist within their
      pancreata. Consequently, the source of persistent insulin secretion within T1D
      remains unclear. We hypothesized low-level insulin content within non-beta-cells 
      could underlie persistent T1D insulin secretion. We tested for low amounts of
      insulin (insulin(low)) within a large cohort of JDRF nPOD human pancreata across 
      a wide range of ages and T1D disease durations. Long exposures, high-throughput
      imaging, and blinded parallel examiners allowed precise quantification of
      insulin(low) cells. Surprisingly, abundant islet endocrine cells with low
      quantities of insulin were present in most T1D pancreata. Insulin(low) islet
      abundance and composition was not influenced by age, duration of diabetes, or age
      of onset. Insulin(low) islets also contained beta-cell markers at variable
      levels, including Pdx1, Nkx6.1, GLUT1, and PC1/3. Most insulin(low) cells
      contained abundant glucagon and other alpha-cell markers, suggesting that
      alpha-cells drive much of the insulin(low) phenotype in T1D. But, PP-, SS-, and
      ghrelin cells also contributed to the insulin(low) cell population. Insulin(low) 
      cells represent a potential source of persistent insulin secretion in
      longstanding T1D and a possible target for regenerative therapies to expand
      beta-cell function in disease.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Lam, Carol J
AU  - Lam CJ
AD  - McNair Medical Institute, Baylor College of Medicine, Houston, TX, 77030.
FAU - Chatterjee, Ani
AU  - Chatterjee A
AD  - McNair Medical Institute, Baylor College of Medicine, Houston, TX, 77030.
FAU - Shen, Emily
AU  - Shen E
AD  - McNair Medical Institute, Baylor College of Medicine, Houston, TX, 77030.
FAU - Cox, Aaron R
AU  - Cox AR
FAU - Kushner, Jake A
AU  - Kushner JA
AD  - McNair Medical Institute, Baylor College of Medicine, Houston, TX, 77030
      jake.kushner@mac.com.
AD  - Current Address: McNair Medical Institute and McNair Interests, Houston, TX,
      77024.
LA  - eng
PT  - Journal Article
DEP - 20181214
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/03/12 00:00 [received]
PHST- 2018/11/27 00:00 [accepted]
PHST- 2018/12/16 06:00 [entrez]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
AID - db18-0305 [pii]
AID - 10.2337/db18-0305 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Dec 14. pii: db18-0305. doi: 10.2337/db18-0305.

PMID- 30552108
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Dec 14
TI  - A genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying
      Variants in CSAD/lnc-ITGB7-1 on Chromosome 12q13.13 Associated with
      Susceptibility to Fulminant Type 1 Diabetes.
LID - db180314 [pii]
LID - 10.2337/db18-0314 [doi]
AB  - The first genome-wide association study of fulminant type 1 diabetes mellitus was
      performed in Japanese individuals. As previously reported using a candidate gene 
      approach, a strong association was observed with multiple SNPs in the HLA region,
      and the strongest association was observed with rs9268853 in the class II DR
      region (P=1.56 x 10(-23), odds ratio [OR] 3.18). In addition, rs11170445 in
      CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide
      significance level (P=7.58 x 10(-9), OR 1.96). Fine mapping of the region
      revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P=4.60 x
      10(-9), OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a
      cis-expression quantitative trait locus (eQTL) for ITGB7 that significantly
      increases the expression of this gene. CSAD/lnc-ITGB7-1 was found to be strongly 
      associated with susceptibility to fulminant, but not classical, autoimmune type 1
      diabetes, implicating this locus in the distinct phenotype of fulminant type 1
      diabetes.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Kawabata, Yumiko
AU  - Kawabata Y
AD  - Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty
      of Medicine, Osaka, Japan.
FAU - Nishida, Nao
AU  - Nishida N
AD  - Research Center for Hepatitis and Immunology, National Center for Global Health
      and Medicine, Chiba, Japan.
AD  - Department of Human Genetics, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Awata, Takuya
AU  - Awata T
AD  - Department of Diabetes, Metabolism and Endocrinology, International University of
      Health and Welfare Hospital, Tochigi, Japan.
FAU - Kawasaki, Eiji
AU  - Kawasaki E
AD  - Diabetes Center, Shin-Koga Hospital, Fukuoka, Japan.
FAU - Imagawa, Akihisa
AU  - Imagawa A
AD  - Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan.
FAU - Shimada, Akira
AU  - Shimada A
AD  - Department of Endocrinology and Diabetes, Saitama Medical University, Saitama,
      Japan.
FAU - Osawa, Haruhiko
AU  - Osawa H
AD  - Department of Laboratory Medicine, Ehime University School of Medicine, Ehime,
      Japan.
FAU - Tanaka, Shoichiro
AU  - Tanaka S
AD  - Ai Home Clinic Toshima, Tokyo, Japan.
FAU - Takahashi, Kazuma
AU  - Takahashi K
AD  - Faculty of Nursing and Graduate School Nursing, Iwate Prefectural University,
      Iwate, Japan.
FAU - Nagata, Masao
AU  - Nagata M
AD  - Department of Internal Medicine, Takasago Municipal Hospital, Hyogo, Japan.
FAU - Yasuda, Hisafumi
AU  - Yasuda H
AD  - Division of Health Sciences, Department of Public Health, Kobe University
      Graduate School of Health Sciences, Hyogo, Japan.
FAU - Uchigata, Yasuko
AU  - Uchigata Y
AD  - Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo,
      Japan.
FAU - Kajio, Hiroshi
AU  - Kajio H
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal
      Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
FAU - Makino, Hideichi
AU  - Makino H
AD  - Diabetes Center, Shiraishi Hospital, Ehime, Japan.
FAU - Yasuda, Kazuki
AU  - Yasuda K
AD  - Department of Metabolic Disorder, Diabetes Research Center, Research Institute,
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
FAU - Hanafusa, Toshiaki
AU  - Hanafusa T
AD  - Sakai City Medical Center, Osaka, Japan.
FAU - Tokunaga, Katsushi
AU  - Tokunaga K
AD  - Department of Human Genetics, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan ikegami@med.kindai.ac.jp tokunaga@m.u-tokyo.ac.jp.
FAU - Ikegami, Hiroshi
AU  - Ikegami H
AD  - Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty
      of Medicine, Osaka, Japan ikegami@med.kindai.ac.jp tokunaga@m.u-tokyo.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20181214
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/12/16 06:00
MHDA- 2018/12/16 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/03/15 00:00 [received]
PHST- 2018/12/04 00:00 [accepted]
PHST- 2018/12/16 06:00 [entrez]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2018/12/16 06:00 [medline]
AID - db18-0314 [pii]
AID - 10.2337/db18-0314 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Dec 14. pii: db18-0314. doi: 10.2337/db18-0314.

PMID- 30559243
OWN - NLM
STAT- In-Data-Review
LR  - 20190109
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - Disclosures: Standards of Medical Care in Diabetes-2019.
PG  - S184-S186
LID - 10.2337/dc19-Sdis01 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S184 [pii]
AID - 10.2337/dc19-Sdis01 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S184-S186. doi: 10.2337/dc19-Sdis01.

PMID- 30559242
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 16. Diabetes Advocacy: Standards of Medical Care in Diabetes-2019.
PG  - S182-S183
LID - 10.2337/dc19-S016 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S182 [pii]
AID - 10.2337/dc19-S016 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S182-S183. doi: 10.2337/dc19-S016.

PMID- 30559241
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2019.
PG  - S173-S181
LID - 10.2337/dc19-S015 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S173 [pii]
AID - 10.2337/dc19-S015 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S173-S181. doi: 10.2337/dc19-S015.

PMID- 30559240
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 14. Management of Diabetes in Pregnancy: Standards of Medical Care in
      Diabetes-2019.
PG  - S165-S172
LID - 10.2337/dc19-S014 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S165 [pii]
AID - 10.2337/dc19-S014 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S165-S172. doi: 10.2337/dc19-S014.

PMID- 30559239
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 13. Children and Adolescents: Standards of Medical Care in Diabetes-2019.
PG  - S148-S164
LID - 10.2337/dc19-S013 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S148 [pii]
AID - 10.2337/dc19-S013 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S148-S164. doi: 10.2337/dc19-S013.

PMID- 30559238
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 12. Older Adults: Standards of Medical Care in Diabetes-2019.
PG  - S139-S147
LID - 10.2337/dc19-S012 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S139 [pii]
AID - 10.2337/dc19-S012 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S139-S147. doi: 10.2337/dc19-S012.

PMID- 30559237
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 11. Microvascular Complications and Foot Care: Standards of Medical Care in
      Diabetes-2019.
PG  - S124-S138
LID - 10.2337/dc19-S011 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S124 [pii]
AID - 10.2337/dc19-S011 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138. doi: 10.2337/dc19-S011.

PMID- 30559236
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in
      Diabetes-2019.
PG  - S103-S123
LID - 10.2337/dc19-S010 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S103 [pii]
AID - 10.2337/dc19-S010 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123. doi: 10.2337/dc19-S010.

PMID- 30559235
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in
      Diabetes-2019.
PG  - S90-S102
LID - 10.2337/dc19-S009 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S90 [pii]
AID - 10.2337/dc19-S009 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102. doi: 10.2337/dc19-S009.

PMID- 30559234
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical 
      Care in Diabetes-2019.
PG  - S81-S89
LID - 10.2337/dc19-S008 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S81 [pii]
AID - 10.2337/dc19-S008 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S81-S89. doi: 10.2337/dc19-S008.

PMID- 30559233
OWN - NLM
STAT- In-Data-Review
LR  - 20190109
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019.
PG  - S71-S80
LID - 10.2337/dc19-S007 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S71 [pii]
AID - 10.2337/dc19-S007 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S71-S80. doi: 10.2337/dc19-S007.

PMID- 30559232
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019.
PG  - S61-S70
LID - 10.2337/dc19-S006 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S61 [pii]
AID - 10.2337/dc19-S006 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70. doi: 10.2337/dc19-S006.

PMID- 30559231
OWN - NLM
STAT- In-Data-Review
LR  - 20181218
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - Suppl 1
DP  - 2019 Jan
TI  - 5. Lifestyle Management: Standards of Medical Care in Diabetes-2019.
PG  - S46-S60
LID - 10.2337/dc19-S005 [doi]
AB  - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes"
      includes ADA's current clinical practice recommendations and is intended to
      provide the components of diabetes care, general treatment goals and guidelines, 
      and tools to evaluate quality of care. Members of the ADA Professional Practice
      Committee, a multidisciplinary expert committee, are responsible for updating the
      Standards of Care annually, or more frequently as warranted. For a detailed
      description of ADA standards, statements, and reports, as well as the
      evidence-grading system for ADA's clinical practice recommendations, please refer
      to the Standards of Care Introduction Readers who wish to comment on the
      Standards of Care are invited to do so at professional.diabetes.org/SOC.
CI  - (c) 2018 by the American Diabetes Association.
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/12/19 06:00
MHDA- 2018/12/19 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2018/12/19 06:00 [medline]
AID - 42/Supplement_1/S46 [pii]
AID - 10.2337/dc19-S005 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(Suppl 1):S46-S60. doi: 10.2337/dc19-S005.